Search results for "Delayed-Action Preparation"

showing 10 items of 101 documents

Different Dissolution Media Lead to Different Crystal Structures of Talinolol with Impact on Its Dissolution and Solubility

2003

During the performance of dissolution tests with immediate and controlled-release talinolol tablets it was detected that the type of the buffer used as dissolution medium had a strong influence on the solubility and the dissolution behavior of the drug. It was proven that talinolol appeared in different crystal structures with strongly differing solubilities when pure water, acetate, or phosphate buffers were employed as dissolution media. The resulting crystal structures were characterized by means of light microscopy, differential scanning calorimetry, and X-ray powder diffraction. All methods were adjuvant to detect changes in talinolol crystal structures. The different solubility and di…

Surface PropertiesSodiumAdrenergic beta-AntagonistsPharmaceutical Sciencechemistry.chemical_elementSodium ChlorideDosage formlaw.inventionPropanolamineschemistry.chemical_compoundX-Ray DiffractionPulmonary surfactantlawDrug DiscoverySolubilityCrystallizationDissolutionPharmacologyChromatographyCalorimetry Differential ScanningChemistryOsmolar ConcentrationOrganic ChemistryHydrogen-Ion ConcentrationSolubilityIonic strengthDelayed-Action PreparationsSolventsCrystallizationTalinololNuclear chemistryDrug Development and Industrial Pharmacy
researchProduct

PHEA-graft-polybutylmethacrylate copolymer microparticles for delivery of hydrophobic drugs.

2012

Abstract Polymeric microparticles encapsulating two model hydrophobic drugs, beclomethasone dipropionate (BDP) and flutamide (FLU) were prepared by using the high pressure homogenization-solvent evaporation method starting from a oil-in-water emulsion. For the preparation of polymeric microparticles a α,β-poly(N-2-hydroxyethyl)- d , l -aspartamide (PHEA) graft copolymer with comb like structure was properly synthesized via grafting from atom transfer radical polymerization (ATRP) technique, by using two subsequent synthetic steps. In the first step a polymeric multifunctional macroinitiator was obtained by the conjugation of a proper number of 2-bromoisobutyryl bromide (BIB) residues to the…

Time FactorsBioadhesivePharmaceutical ScienceCell LineDrug Delivery SystemsPolymethacrylic AcidsPolymer chemistryMucoadhesionCopolymerSide chainHumansPhea polybutylmethacrylate microparticles drug deliveryParticle SizeGlucocorticoidsDrug CarriersDose-Response Relationship DrugChemistryAtom-transfer radical-polymerizationBeclomethasoneAdhesivenessAndrogen AntagonistsGraftingFlutamideMicrospheresPolymerizationDelayed-Action PreparationsEmulsionSolventsNanoparticlesEmulsionsCaco-2 CellsPeptidesHydrophobic and Hydrophilic InteractionsInternational journal of pharmaceutics
researchProduct

SYNTHESIS, CHARACTERIZATION AND IN VITRO CYTOTOXICITY STUDIES OF A MACROMOLECULAR CONJUGATE OF PACLITAXEL BEARING OXYTOCIN AS TARGETING MOIETY.

2007

The present study describes the experimental synthetic procedure and the characterization of a new polyaspartamide macromolecular prodrug of paclitaxel, bearing oxytocin residues as targeting moieties. In vitro stability studies of bioconjugate, performed in media mimicking biological fluids (buffer solutions at pH 7.4 and 5.5) and in human plasma, evidenced the high stability of the targeting portion (oxytocin)-polymer linkage and the ability of this conjugate to release linked paclitaxel in a prolonged way in plasma. Moreover, preliminary in vitro antiproliferative studies, carried out on MCF-7 cells, that are oxytocin receptor positive cells, showed that the polymeric conjugate has the s…

Time FactorsChemistry PharmaceuticalDrug CompoundingpolyaspartamidePharmaceutical ScienceBreast NeoplasmsPolyethylene Glycolschemistry.chemical_compoundpaclitaxelDrug StabilityCell Line TumoroxytocinHumansMoietyProdrugsbioconjugateCytotoxicityCell ProliferationDrug CarriersDose-Response Relationship DrugMolecular StructureHydrolysisdrug targetingGeneral MedicineHydrogen-Ion ConcentrationAntineoplastic Agents PhytogenicOxytocin receptorIn vitroSolubilityPaclitaxelchemistryBiochemistryTargeted drug deliveryReceptors OxytocinDelayed-Action PreparationsFemalePeptidesDrug carrierBiotechnologyConjugate
researchProduct

Prostaglandin E(2)-loaded microspheres as strategy to inhibit phagocytosis and modulate inflammatory mediators release.

2008

PGE(2), an arachidonic acid metabolite produced by various type of cells regulates a broad range of physiological activities in the endocrine, cardiovascular, gastrointestinal, and immune systems, and is involved in maintaining the local homeostasis. In the immune system, PGE(2) is mainly produced by APCs and it can suppress the Th1-mediated immune responses. The aim of this study was to develop PGE(2)-loaded biodegradable MS that prolong and sustain the in vivo release of this mediator. An o/w emulsion solvent extraction-evaporation method was chosen to prepare the MS. We determined their diameters, evaluated the in vitro release of PGE(2), using enzyme immunoassay and MS uptake by periton…

Time Factorsmedicine.medical_treatmentPhagocytosisChemistry PharmaceuticalDrug CompoundingPharmaceutical ScienceInflammationPharmacologyBiologyNitric OxideDinoprostonechemistry.chemical_compoundMiceImmune systemPhagocytosisIn vivoSepsismedicineAnimalsHumansImmunologic FactorsProstaglandin E2Particle SizeCells CulturedChemokine CCL2Tumor Necrosis Factor-alphaEndothelial CellsWaterGeneral MedicineMicrospheresDisease Models AnimalchemistryBiochemistrySolubilityDelayed-Action PreparationsMacrophages PeritonealLiberationlipids (amino acids peptides and proteins)Arachidonic acidEmulsionsmedicine.symptomInflammation MediatorsOilsBiotechnologyProstaglandin Emedicine.drugEuropean journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
researchProduct

Nano into Micro Formulations of Tobramycin for the Treatment of Pseudomonas aeruginosa Infections in Cystic Fibrosis.

2017

Here, nano into micro formulations (NiMs) of tobramycin for the treatment of Pseudomonas aeruginosa airway infections in cystic fibrosis (CF) are described. NiMs were produced by spray drying a solution containing polymers or sugars and a nanometric polyanion–tobramcyin complex (PTC), able to achieve a prolonged antibiotic release. NiMs properties were compared to TOBIPodhaler(Novartis), the only one commercially available dry powder inhalatory formulation based on porous microparticles. Produced NiMs showed adequate characteristics for pulmonary administration, as spherical shape, micrometric size, and high cytocompatibility toward human bronchial epithelial cells. Contrarily to TOBIPodhal…

Tobramycin Cystic Fibrosis Artificial Mucus (CF-AM) αβ-poly-(N-2-hydroxyethyl)-DL-aspartamide (PHEA) ion pair complex nano into micro strategy Pseudomonas aeruginosa infections biofilmPolymers and PlasticsCystic FibrosisPolymersChemistry PharmaceuticalBioengineeringBronchi02 engineering and technologymedicine.disease_causeCystic fibrosisMicrobiologyBiomaterials03 medical and health sciences0302 clinical medicineDrug Delivery SystemsNano-Materials ChemistrymedicineTobramycinHumansPseudomonas InfectionsParticle SizeRespiratory Tract InfectionsCells CulturedDrug CarriersPseudomonas aeruginosaChemistryBiofilmDry Powder InhalersEpithelial Cells021001 nanoscience & nanotechnologyAntimicrobialmedicine.diseaseMucusPolyelectrolytesAnti-Bacterial Agents030228 respiratory systemSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoSpray dryingBiofilmsDelayed-Action PreparationsPseudomonas aeruginosaTobramycinNanoparticles0210 nano-technologymedicine.drugBiomacromolecules
researchProduct

Absorption of oxybutynin from vaginal inserts: drug blood levels and the response of the rabbit bladder.

2000

Abstract Objectives. Oxybutynin has been used for treatment of urge urinary incontinence for more than 20 years. However, one of the major problems with its use is uncomfortable anticholinergic side effects that can lead to discontinuation of treatment. Alternative forms of drug administration may reduce side effects and thus improve patient compliance. Methods. A cylinder-shaped, curved silicone elastomer insert containing oxybutynin was anchored in the vagina of female rabbits. The inserts were designed to release oxybutynin at rates of 0.5, 1.0, and 5.0 mg/day, respectively. Blood drug and metabolite levels were monitored for 1 to 7 days and cystometry was carried out after 7 days of tre…

Urologymedia_common.quotation_subjectUrinary Bladdermedicine.disease_causeUrinationAbsorptionBlood drugMedicineAnimalsOxybutyninActive metabolitemedia_commonUrinary bladdermedicine.diagnostic_testbusiness.industryCystometryParasympatholyticsAdministration Intravaginalmedicine.anatomical_structureAnesthesiaDelayed-Action PreparationsVaginaVaginaSilicone ElastomersMandelic AcidsFemaleRabbitsIrritationbusinessmedicine.drugComplianceUrology
researchProduct

Ocular gelling microspheres: in vitro precorneal retention time and drug permeation through reconstituted corneal epithelium.

2008

Purpose: The model drug norfloxacin (NOR)was encapsulated into trehalose (TRH) and hydroxyethylcellulose(NAT) microspheres to obtain a novel gelling ophthalmic delivery system for prolonged release on corneal tissue. Methods: We assessed NOR release from microspheres, prepared by the emulsion-solvent evaporation method. A new in vitro tear turnover model, including inserts containing reconstituted human corneal epithelium (RHC), was designed to evaluate the TRH/NAT microspheres’ precorneal retention time. Bioadhesive properties of TRH/NAT microspheres were validated by using drug-loaded microspheres prepared with gelatine (GLT) commonly used as reference material in adhesion studies. Result…

endocrine systemmedicine.medical_specialtyBioadhesiveBiological AvailabilityReconstituted corneal epitheliumIn Vitro TechniquesDOSAGE FORMSPermeabilityDelayed-Action PreparationsAqueous Humorchemistry.chemical_compoundCorneamedicineHumansPharmacology (medical)CONTAINING LIPOSOMESCelluloseOcular microsphereCorneal epitheliumCell Line TransformedPharmacologyChromatographyEpithelium CornealAdhesivenessTrehaloseDELIVERY SYSTEMTrehaloseIn vitroMicrospheresSurgeryAnti-Bacterial AgentsTREHALOSE-HYDROXYETHYLCELLULOSE MICROSPHERESOphthalmologymedicine.anatomical_structurechemistrySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoPermeability (electromagnetism)SOLUTE RELEASEDelayed-Action PreparationsGelatinSwellingmedicine.symptomOphthalmic SolutionsGelsNorfloxacinJournal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
researchProduct

Combined oral prolonged-release oxycodone and naloxone in chronic pain management

2013

Introduction: The use of opioids is associated with unwanted adverse effects, particularly opioid-induced constipation (OIC). The adverse effects of opioids on gastrointestinal function are mediated by the interaction with opioid receptors in the gastrointestinal tract. The most common drugs used for relieving OIC are laxatives, which do not address the opioid receptor-mediated bowel dysfunction and do not provide sufficient relief. Areas covered: This paper discusses the role of a combination of prolongedrelease formulation of oxycodone (OX) and naloxone (N) in the prevention and management of OIC, reporting efficacy and safety outcome of controlled studies. In a therapeutic area of great …

medicine.drug_classSettore MED/41 - Anestesiologiacancer pain chronic pain opioid-antagonist opioids oxycodone--naloxone combinationNaloxonemedicineHumansPharmacology (medical)Adverse effectPharmacologybusiness.industryNaloxoneChronic painGeneral Medicinemedicine.diseaseAnalgesics OpioidDrug CombinationsTreatment OutcomeOpioidAnesthesiaDelayed-Action PreparationsChronic PainGastrointestinal functionbusinessCancer painOxycodoneOpioid antagonistOxycodonemedicine.drug
researchProduct

Oxycodone extended release capsules for the treatment of chronic pain

2017

As a consequence of greater prescription opioid utilization, there has been the parallel increase in misuse, abuse, and overdose, which are serious risks. Associated new formulations may be safer. Areas covered: The introduction of abuse-deterrent opioid formulations and continuous programs to improve opioid prescribing practices may limit the opioid abuse and its consequences. Oxycodone extended release capsules are an extended-release (ER), microsphere-in-capsule abuse-deterrent-formulation designed to retain its extended-release properties following tampering or misuse (e.g., chewing, crushing). Studies have reported that this preparation is efficacious in patients with low back pain, le…

medicine.medical_specialtyCapsules03 medical and health sciences0302 clinical medicine030202 anesthesiologymedicineHumansPharmacology (medical)In patientChildIntensive care medicinebusiness.industryGeneral NeuroscienceChronic painHave Difficulty Swallowingmedicine.diseaseLow back painAnalgesics OpioidOpioidPrescription opioidDelayed-Action PreparationsAnesthesiaNeurology (clinical)Chronic Painmedicine.symptomExtended releasebusinessOxycodoneOxycodone030217 neurology & neurosurgerymedicine.drugExpert Review of Neurotherapeutics
researchProduct

BMP-2 and bFGF release and in vitro effect on human osteoblasts after adsorption to bone grafts and biomaterials.

2012

Objectives Combination of scaffolds and growth factors is a promising option for several clinical problems in bone biomaterials. Simplified growth factor loading by adsorption from aqueous solution is one important option for this technology. We evaluated the adsorption followed by PBS rinsing, release and biological effect of transient loading with basic fibroblast growth factor (bFGF) and bone morphogenic protein 2 (BMP-2) on fresh frozen bone, processed bone matrix, collagen, and a ceramic material with immunofluorescence, enzyme-linked immunosorbent assay (ELISA), and qRT-PCR. Materials and methods The study consisted of three in vitro experiments (immunofluorescence, ELISA, and qRT-PCR…

medicine.medical_specialtyCeramicsTime Factorsmedicine.medical_treatmentBasic fibroblast growth factorOsteocalcinCell Culture TechniquesBone MatrixBone Morphogenetic Protein 2Fluorescent Antibody TechniqueBiocompatible MaterialsCore Binding Factor Alpha 1 SubunitEnzyme-Linked Immunosorbent AssayBone healingMatrix (biology)Bone morphogenetic proteinBone morphogenetic protein 2Bone and Boneschemistry.chemical_compoundmedicineAnimalsHumansCells CulturedOsteoblastsbiologyTissue ScaffoldsReverse Transcriptase Polymerase Chain ReactionGrowth factorOsteoblastAlkaline PhosphataseSurgerymedicine.anatomical_structureDurapatitechemistryDelayed-Action PreparationsOsteocalcinbiology.proteinBiophysicsNanoparticlesFibroblast Growth Factor 2AdsorptionCollagenOral SurgeryBiomarkersClinical oral implants research
researchProduct